Zacks Research Has Weak Estimate for OPKO Health Q2 Earnings

Key Points

• Zacks Research cut its Q2 2028 EPS estimate for OPKO Health to -$0.05 from -$0.04, signaling a slightly weaker outlook for the quarter. The firm’s full-year earnings estimate remains deeply negative at -$0.29 per share.
• OPKO Health’s most recent quarterly results showed EPS of -$0.07, matching expectations, but revenue of $124.2 million came in below the $130.51 million forecast. Revenue also fell 17.1% year over year.
• Wall Street sentiment remains cautious: the stock has an average rating of “Reduce” with a consensus target price of $1.55. OPKO shares were trading at $1.35 and the company has a market cap of about $1.02 billion.

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Equities research analysts at Zacks Research reduced their Q2 2028 earnings per share (EPS) estimates for shares of OPKO Health in a report issued on Thursday, July 9th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings per share of ($0.05) for the quarter, down from their prior forecast of ($0.04). The consensus estimate for OPKO Health's current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for OPKO Health's FY2028 earnings at ($0.19) EPS.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07). The company had revenue of $124.20 million for the quarter, compared to analysts' expectations of $130.51 million. OPKO Health had a negative return on equity of 16.78% and a negative net margin of 36.63%.The firm's revenue for the quarter was down 17.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.10) earnings per share.

Several other brokerages have also issued reports on OPK. Wall Street Zen upgraded shares of OPKO Health from a "sell" rating to a "hold" rating in a research note on Saturday, June 6th. Weiss Ratings raised shares of OPKO Health from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, May 18th. Finally, Barrington Research cut shares of OPKO Health from an "outperform" rating to a "market perform" rating in a report on Wednesday, April 29th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Reduce" and a consensus target price of $1.55.

OPKO Health Stock Performance

Shares of OPK stock opened at $1.35 on Monday. OPKO Health has a 12 month low of $0.98 and a 12 month high of $1.61. The stock has a market cap of $1.02 billion, a PE ratio of -5.00 and a beta of 1.48. The company has a current ratio of 3.61, a quick ratio of 3.17 and a debt-to-equity ratio of 0.28. The company's fifty day moving average price is $1.35 and its 200-day moving average price is $1.27.

Hedge Funds Weigh In On OPKO Health

A number of hedge funds have recently bought and sold shares of the business. Comerica Bank increased its position in shares of OPKO Health by 7.1% during the 4th quarter. Comerica Bank now owns 120,000 shares of the biotechnology company's stock valued at $151,000 after purchasing an additional 8,000 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of OPKO Health by 4.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 198,148 shares of the biotechnology company's stock worth $262,000 after buying an additional 8,954 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of OPKO Health by 11.2% in the second quarter. The Manufacturers Life Insurance Company now owns 138,643 shares of the biotechnology company's stock worth $183,000 after buying an additional 13,912 shares during the last quarter. Intech Investment Management LLC grew its position in OPKO Health by 11.4% during the fourth quarter. Intech Investment Management LLC now owns 159,652 shares of the biotechnology company's stock valued at $201,000 after buying an additional 16,329 shares during the period. Finally, Swiss Life Asset Management Ltd bought a new stake in OPKO Health during the third quarter valued at approximately $30,000. Hedge funds and other institutional investors own 64.63% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc NASDAQ: OPK is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.